Functional dyspepsia and disorders of gut-brain interaction

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Dyspepsia describes upper abdominal symptoms, whereas functional dyspepsia is a positive diagnosis within the disorders of gut-brain interaction. Identify the dominant experience: uncomfortable fullness after an ordinary meal, inability to finish a normal portion, localised epigastric pain or burning. Establish timing, meal relationship, weight trajectory, vomiting, reflux, bowel symptoms and medicine exposure. Delayed gastric emptying, impaired fundic accommodation, duodenal signalling, visceral hypersensitivity and central amplification may each contribute, but no routine biomarker assigns a mechanism to an individual. Functional dyspepsia commonly overlaps IBS, reflux, nausea syndromes and anxiety; overlap should broaden an integrated plan rather than create a sequence of competing labels.

Before making the diagnosis, triage structural and extra-gastrointestinal threats. Ask about dysphagia, bleeding, anaemia, progressive vomiting, mass, family history, NSAIDs and age-related cancer risk. Consider acute coronary syndrome when epigastric pressure is exertional or autonomic; gallstone disease when discrete sustained attacks reach the right upper quadrant or back; pancreatitis with persistent severe back-radiating pain and illness. In an uncomplicated presentation, NICE supports H pylori test-and-treat and a four-week full-dose PPI trial. Apply the current NG12 symptom combinations rather than memorising one age cut-off. Endoscopy answers alarm or persistent structural questions but should not become a periodic reassurance ritual.

Treatment needs a coherent explanation and staged choices. Regular modest meals may reduce accommodation demand, while aerobic activity and sleep support overall symptom regulation. Test and eradicate H pylori correctly and stop NSAIDs where feasible. A PPI may help even when the eventual diagnosis is functional, but response is not proof of acid disease and treatment should be stepped down after review. For persistent pain, a low-dose TCA is used as a gut-brain neuromodulator, generally at a dose below antidepressant treatment. A prokinetic may suit selected postprandial symptoms, but UK availability, cardiac risk and local formularies constrain choice. Dietetic review protects nutrition when early satiation causes restriction, and gut-directed psychological therapy can improve coping and symptom processing without implying psychiatric causation.

Key points

Functional dyspepsia is a disorder of gut-brain interaction producing epigastric pain or burning, early satiation or postprandial fullness without structural disease that adequately explains the symptoms.
Postprandial distress syndrome is dominated by meal-related fullness and early satiation; epigastric pain syndrome centres on pain or burning, and overlap is common.
Ask separately about retrosternal heartburn, biliary attacks, pancreatic pain, exertional pressure, vomiting and dysphagia because these imply different tests and pathways.
Use Helicobacter pylori test-and-treat and a time-limited full-dose proton-pump inhibitor strategy for suitable uninvestigated dyspepsia, sequencing them according to NICE and local practice.
A urea breath or stool-antigen test needs a two-week PPI washout and the required interval after antibiotics; a poorly prepared negative result is not reassuring.
Normal endoscopy supports a functional diagnosis only after the indication, quality, biopsies and alternative biliary, pancreatic, metabolic or motility questions are reconsidered.
Explain visceral hypersensitivity, impaired accommodation and gut-brain signalling as plausible mechanisms while making clear that psychological distress may modify symptoms but does not fabricate them.
Use regular smaller meals, exercise and selective acid suppression or low-dose tricyclic neuromodulation; avoid broad unsupported food bans and repetitive investigations.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Gut-brain susceptibility

Altered visceral sensation, autonomic regulation and central pain processing interact with personality and life experience without making symptoms psychologically fabricated.

Post-infective and mucosal factors

Some cases follow gastroenteritis or show subtle duodenal immune and barrier changes, linking luminal events to persistent sensory dysfunction.

Psychosocial and medicine modifiers

Stress, anxiety, sleep disturbance and medicines affecting gastric motility can amplify symptoms, while none alone proves the diagnosis.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Impaired gastric accommodation
The proximal stomach may relax inadequately after eating, producing early satiation and uncomfortable fullness from ordinary meal volumes.
2
Motility and duodenal signalling
Variable gastric emptying and altered duodenal nutrient or immune responses generate postprandial symptoms without fixed obstruction.
3
Visceral hypersensitivity
Enhanced peripheral and central processing makes normal distension or acid exposure painful and sustains symptoms after structural disease is excluded.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Postprandial distress phenotype

Troublesome fullness after ordinary meals and early satiation predominate, sometimes with upper bloating or nausea. Recurrent effortless vomiting, substantial weight loss or retained food suggests another gastric disorder.

Epigastric pain phenotype

Intermittent pain or burning centred in the epigastrium without a consistent bowel relationship supports epigastric pain syndrome after ulcer, biliary, pancreatic and cardiac alternatives have been assessed.

Upper gastrointestinal alarmRed flag

Progressive dysphagia, haematemesis, melaena, iron-deficiency anaemia, persistent vomiting, palpable mass or qualifying unexplained weight loss activates urgent structural and cancer assessment rather than routine functional treatment.

Gastroparesis or obstruction signal

Repeated vomiting of food eaten hours earlier, severe postprandial distension, diabetes, connective-tissue disease or previous gastric surgery may justify structural exclusion and formal gastric-emptying assessment rather than an empirical label.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Helicobacter pylori breath or stool-antigen testFirst step
Why
Detect active infection and select eradication treatment in uncomplicated uninvestigated dyspepsia.
Interpretation and limitations
Hold PPI treatment for two weeks when clinically safe and observe the assay interval after antibiotics. A positive result warrants local eradication; serology can remain positive and generally cannot confirm cure.
02
Full blood count and ferritin
Why
Identify iron deficiency or blood loss that changes endoscopy urgency and challenges a functional diagnosis.
Interpretation and limitations
Anaemia or depleted iron stores need explanation through the appropriate upper and lower gastrointestinal pathway. Normal indices do not neutralise progressive dysphagia or a palpable mass.
03
Upper gastrointestinal endoscopy
Why
Visualise and biopsy suspected cancer, ulcer, oesophagitis or other mucosal disease when alarms or persistent discordant symptoms justify it.
Interpretation and limitations
A high-quality normal procedure supports functional dyspepsia, but only after reviewing whether H pylori, coeliac, biliary, pancreatic or motility questions remain unanswered.
04
Liver profile and lipase
Why
Investigate sustained upper-abdominal pain, jaundice or systemic illness for hepatobiliary disease and acute pancreatitis.
Interpretation and limitations
A cholestatic pattern supports biliary imaging, while lipase elevation with compatible pain supports pancreatitis. Routine normal results do not independently prove functional dyspepsia.
05
ECG and cardiac biomarkers
Why
Evaluate epigastric symptoms with exertional, autonomic or cardiovascular-risk features for acute coronary syndrome.
Interpretation and limitations
Follow the acute chest-pain pathway; one normal ECG may not exclude evolving ischaemia. Do not delay serial assessment while administering an antacid trial.
06
Gastric-emptying study
Why
Test delayed emptying only when persistent vomiting, diabetes, surgery or another strong motility phenotype remains after obstruction is excluded.
Interpretation and limitations
Use a validated specialist protocol and interpret medicines and glycaemia that alter emptying. Delayed emptying and symptom severity correlate imperfectly and require clinicophysiological review.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Peptic ulcer or gastric cancer

Anaemia, weight loss, persistent vomiting, bleeding, dysphagia or an abnormal examination requires endoscopy rather than a functional diagnosis.

Biliary or pancreatic disease

Discrete right-upper-quadrant attacks, jaundice, back-radiating persistent pain or abnormal imaging and enzymes indicate hepatopancreatobiliary pathology rather than functional dyspepsia.

Cardiac ischaemia or GORD

Exertional pressure and cardiovascular risk require cardiac evaluation, while dominant retrosternal heartburn and regurgitation favour reflux disease.

Additional chapter-specific clues

Biliary or pancreatic alternativeRed flag

Discrete prolonged right upper-quadrant or epigastric attacks with back or shoulder radiation suggest gallstone disease; continuous severe pain, vomiting and systemic illness raise pancreatitis and require targeted testing.

Cardiac mimicRed flag

Exertional epigastric pressure with dyspnoea, sweating, radiation or cardiovascular risk demands ECG-led acute coronary assessment. Meal association and temporary antacid response cannot safely exclude myocardial ischaemia.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01TriageSeparate functional from urgent structural diseaseFirst stepA person presents with epigastric pain, burning, early satiation or post-meal fullness.

1Assess physiology and exclude bleeding, perforation, cardiac ischaemia, pancreatitis and biliary sepsis before considering a routine dyspepsia pathway.
2Ask about dysphagia, vomiting, weight loss, anaemia, mass, family history, NSAIDs and age-linked onset, then apply current NG12 and endoscopy criteria.
3Define whether symptoms are meal distress, epigastric pain, reflux, vomiting or discrete biliary attacks and select investigations that address that phenotype.
4Record the intended review interval and specific triggers for urgent reassessment even when initial management remains in primary care.

02Initial dyspepsiaTest and treat in a deliberate sequenceUninvestigated dyspepsia is stable and has no urgent endoscopy indication.

1Review NSAIDs and other offending medicines, provide regular-meal advice and choose H pylori test-and-treat or a four-week full-dose PPI trial under NICE and local practice.
2If testing for H pylori, arrange appropriate PPI and antibiotic washout, use a validated active-infection assay and establish who will action the result.
3Treat confirmed infection with the locally recommended resistance-aware regimen, checking allergy, interactions and previous antibiotic exposure.
4Review symptom response after the planned intervention, step down PPI treatment where safe and revisit the diagnosis rather than renewing empirically forever.

03Persistent functional symptomsLayer mechanism-based treatmentAppropriate assessment has found no explanatory structural disease and symptoms remain intrusive.

1Explain the functional diagnosis and dominant subtype, linking altered accommodation and sensitivity to real symptoms without asserting a single unmeasured cause.
2Use smaller regular meals, aerobic activity and dietetic help if early satiation or food fear threatens nutrition; avoid unsupported universal restriction.
3Match treatment to phenotype, considering acid suppression, a low-dose TCA for pain or a locally available specialist prokinetic for selected postprandial symptoms.
4Offer gut-directed psychological therapy and specialist review for refractory burden, while repeating investigation only when the phenotype or warning features genuinely change.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Treats acid-responsive symptoms and may improve functional dyspepsia, while also supporting healing when unsuspected acid-mediated disease is present.

Proton-pump inhibitor

Use a current NICE full-dose preparation for a four-week empirical dyspepsia course, then step down to the lowest effective or intermittent strategy after review.

Stop for two weeks before H pylori breath or stool testing when safe. Review interactions, infection risk and long-term indication, and never let symptomatic response override alarm features.

Eradicates active H pylori, reducing ulcer risk and providing sustained symptom benefit for a minority with associated dyspepsia.

Helicobacter pylori eradication regimen

Use the locally recommended seven-day combination selected for penicillin allergy, prior macrolide or metronidazole exposure and regional resistance information.

Confirm active infection, allergies, pregnancy considerations and interactions. Failed treatment requires adherence and resistance-aware review; do not repeat the same antibiotics blindly or use serology to confirm cure.

Reduces epigastric pain through central and peripheral neuromodulation when first-line explanation, H pylori care and acid suppression are insufficient.

Low-dose tricyclic neuromodulator

Start with the local low nightly dose and increase slowly only after tolerability review; functional-dyspepsia dosing is generally below antidepressant treatment ranges.

Discuss sedation, dry mouth, constipation, urinary retention, glaucoma, falls, cardiac conduction and overdose risk. Obtain ECG or specialist advice when cardiovascular history or interacting medicines warrant it.

May improve meal-related fullness or nausea by modifying gastric motility in a subset whose symptoms fit that mechanism.

Specialist prokinetic

Select and dose only through the current local formulary for a clearly defined postprandial or delayed-emptying phenotype, using the shortest justified trial.

UK availability and licensed indications differ. Review QT and neurological risks, interactions and duration; do not prescribe metoclopramide or domperidone as indefinite unmonitored functional-dyspepsia therapy.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Restrictive eating and weight loss

Fear of postprandial symptoms can progressively shrink meal size, causing avoidant eating, nutritional deficiency and social isolation around food.

Medicine and procedure burden

Repeated acid suppression, antiemetics, opioids or low-yield investigations can cause adverse effects while reinforcing uncertainty and illness behaviour.

Persistent quality-of-life impairment

Chronic pain, fullness and nausea disrupt sleep, work and mood, with symptom severity often exceeding measurable gastric dysfunction.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Measure early satiation, meal completion, vomiting, weight and diet breadth so nutritional decline is recognised before laboratory deficiency appears.
Track H pylori test preparation, result, eradication regimen, adherence and any correctly timed confirmation result with a named clinician responsible for action.
Review PPI benefit after its planned course and document the indication for ongoing treatment, attempting step-down when alarms and structural disease are absent.
After starting a neuromodulator, review sedation, anticholinergic effects, mood, cardiac symptoms and functional benefit before any dose increase.
Treat new dysphagia, bleeding, anaemia, progressive vomiting or weight loss as a changed presentation rather than an expected functional fluctuation.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Phenotype sharpens treatment

Early satiation points towards meal accommodation and nutrition, whereas focal epigastric burning may respond more to acid or pain neuromodulation. The categories overlap but prevent indiscriminate prescribing.

Endoscopy has boundaries

A normal endoscopy excludes many visible mucosal lesions at that time; it does not test gastric emptying, biliary pain or every microscopic condition, nor guarantee against future disease.

Neuromodulator is descriptive

Low-dose TCA treatment targets visceral pain processing rather than declaring depression. Explaining this difference improves informed choice and avoids the damaging message that symptoms are imaginary.

Preparation determines H pylori truth

PPI and recent antibiotics suppress organism detection. A negative test without documented washout may generate false reassurance and inappropriate long-term acid treatment.

Food fear becomes pathology

Severe early satiation may promote progressive avoidance, weight loss and micronutrient risk. Early dietetic support is treatment, not an optional extra after every medicine fails.

11Common pitfallsFrequent interpretation and management errors.

01
Calling exertional epigastric pressure functional dyspepsia without cardiac assessment.
02
Testing for H pylori while a PPI is still suppressing organism detection.
03
Using PPI response as proof that progressive dysphagia or weight loss is benign.
04
Repeating normal endoscopy for unchanged symptoms without a defined clinical question.
05
Prescribing a prokinetic indefinitely without checking its licence, cardiac or neurological risk.
06
Suggesting that gut-brain interaction means the patient has invented or exaggerated symptoms.